Gilead and GSK drugs for HCV and HIV win EU green light

November 22, 2013 5:16 PM

15 0

Gilead and GSK drugs for HCV and HIV win EU green light

LONDON (Reuters) - European regulators have recommended approval of a new drug from Gilead Sciences to treat hepatitis C and an HIV medicine from GlaxoSmithKline, both of which are expected to be major sellers.

The European Medicine Agency (EMA) said on Friday its committee of experts also gave the green light to a tuberculosis drug from Japan's Otsuka, following a review of an earlier rejection.

Read more

To category page

Loading...